5.3 Bibliography

In addition to the references throughout the toolkit, the following is a non-exhaustive list of resources and references that are relevant to SFMPs, organized by module.

5.3.1 General: Selected WHO guidance documents

- Annex 2 Good manufacturing practices for pharmaceutical products: main principles. In: Forty-eighth report of the WHO Expert Committee on specifications for pharmaceutical preparations. Geneva: World Health Organization; 2014 (https://iris.who.int/handle/10665/112733, accessed 26 November 2024).
- Protecting the supply chain: reports on informal markets. In: Member State survey on informal markets and literature review on informal markets. Geneva: World Health Organization; 2023.
- Guidance for post-market surveillance and market surveillance of medical devices, including in vitro diagnostics. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/337551, accessed 26 November 2024).
- Identification of reporting barriers faced by national focal points of the Global Focal Point Network and possible solutions. In: 12th Meeting of the Member State Mechanism on Substandard and Falsified Medical Products. Geneva: World Health Organization. 2023. (https://apps.who.int/gb/sf/pdf_files/MSM12/A_MSM12_5-en.pdf, accessed 12 December 2024).
- Rapid risk assessment of acute public health events. Geneva, World Health Organization, 2012 (https://iris.who.int/handle/10665/70810, accessed 12 December 2024).
- Quality assurance of medicines terminology database: list of terms and related guidelines [internet]. Geneva: World Health Organization; 2023 (https://www.who.int/publications/m/item/quality-assurance-of-medicines-terminology-database, accessed 17 November 2024).
- Annex 1: WHO good pharmacopoeial practices. In: Fiftieth report of the WHO Expert Committee on specifications for pharmaceutical preparations. Geneva: World Health Organization; 2016 (https://iris.who.int/handle/10665/255338, accessed 17 November 2024).
- Annex 4: WHO good practices for pharmaceutical quality control laboratories. In: Fifty seventh report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations. Geneva: World Health Organization, 2024 (https://www.who.int/publications/m/item/who-good-practices-for-pharmaceutical-quality-control-laboratories, accessed 12 Dec 2024).

5.3.2 Module A. Background

WHO guidelines on use and regulation of pharmaceuticals

- A study on the public health and socioeconomic impact of substandard and falsified medical products. Geneva: World Health Organization; 2017 (https://iris.who.int/handle/10665/331690, accessed 26 November 2024).
- Annex 3. Model quality assurance system for procurement agencies. In: Forty-eighth report of the WHO Expert Committee on specifications for pharmaceutical preparations. Geneva: World Health Organization; 2014 (https://iris.who.int/handle/10665/112733, accessed 26 November 2024).
- Annex 3. Reporting form for complaints for medical devices including in vitro diagnostics. In: Report of Africa Medical Devices Forum COVID-19 Task Force. African Medical Device Forum; 2020 (https://www.afro.who.int/publications/report-africa-medical-devices-forum-covid-19-task-force, accessed 26 November 2024).
- Annex 5. Technical supplements to Model guidance for the storage and transport of time and temperature-sensitive pharmaceutical products. In: Forty-ninth report of the WHO Expert Committee on specifications for pharmaceutical preparations. Geneva: World Health Organization; 2011 (https://iris.who.int/handle/10665/176954, accessed 26 November 2024).

- Annex 5. WHO good distribution practices for pharmaceutical products. In: WHO Expert Committee on specifications for pharmaceutical preparations: forty-fourth report. Geneva: World Health Organization; 2010 (https://iris.who.int/handle/10665/44291, accessed 26 November 2024).
- Annex 5. Guidelines on import procedures for medical products. In: Fifty-third report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations. Geneva: World Health Organization; 2019 (https://iris.who.int/handle/10665/312316, accessed 26 November 2024).
- Annex 8 Joint FIP/WHO Guidelines in good pharmacy practice: standards for quality of pharmacy services. In: Forty-fifth report of the WHO Expert Committee on specifications for pharmaceutical preparations. Geneva: World Health Organization; 2011 (https://iris.who.int/handle/10665/44079, accessed 26 November 2024).
- Annex 10. Good reliance practices in the regulation of medical products: high level principles and considerations. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations: fifty-fifth report. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/340323, accessed 26 November 2024).
- Annex 11. Good regulatory practices in the regulation of medical products. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations: fifty-fifth report. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/340323, accessed 26 November 2024).
- Combating substandard and falsified medical products. Geneva: Council for International Organizations of Medical Sciences; 2020 (https://cioms.ch/wp-content/uploads/2020/02/CIOMS-Special-Newsletter_WHO_SF_Meds_20Feb2020_Final.pdf, accessed 26 November 2024).
- Eighth meeting of the Members State Mechanism on substandard and falsified medical products. Problem statement identifying the range of issues that facilitate the sale and supply of substandard and falsified medical products through the internet both nationally and across borders. Geneva: World Health Organization; 2019 (https://apps.who.int/gb/SF/pdf_files/MSM8/A_MSM8_3-en.pdf, accessed 26 Nov 2024).
- Executive Board, 118. Rational use of medicines: progress in implementing the WHO medicines strategy: report by the Secretariat. Geneva: World Health Organization; 2006. (https://iris.who.int/handle/10665/21525, accessed 26 November 2024).
- Expert Committee on Specifications for Pharmaceutical Preparations: fifty-fifth report. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/340323, accessed 26 November 2024).
- Full list of WHO medical product alerts [internet]. Geneva: World Health Organization; 2024 (https://www.who.int/teams/regulation-prequalification/incidents-and-SF/full-list-of-who-medical-product-alerts, accessed 26 November 2024).
- Global surveillance and monitoring system for substandard and falsified medical products. Geneva: World Health Organization; 2017 (https://iris.who.int/handle/10665/326708, accessed 26 November 2024).
- Global competency framework for regulators of medicines. Geneva: World Health Organization; 2023 (https://iris.who.int/handle/10665/374053, accessed 26 November 2024).
- Global benchmarking tool (GBT) for evaluation of national regulatory system of medical products. Geneva: World Health Organization; 2023 (https://iris.who.int/handle/10665/376137, accessed 10 December 2024).
- Guidance for conducting quality surveys (Working Document QAS/15.630). Geneva: World Health Organization, 2015 (https://www.who.int/publications/m/item/qas-15.630, 10 December 2024)
- Guidelines for medicine donations, revised 2010. Geneva: World Health Organization; 2011 (https://iris.who.int/handle/10665/44647, accessed 26 November 2024).

- Guidance for procurement of in vitro diagnostics and related laboratory items and equipment. Geneva: World Health Organization; 2017 (https://iris.who.int/handle/10665/255577, accessed 26 November 2024).
- Guidance for post-market surveillance and market surveillance of medical devices, including in vitro diagnostics. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/337551, accessed 26 November 2024).
- Health products policy and standards: guidelines on production [internet]. Geneva: World Health Organization; 2024 (https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/norms-and-standards-for-pharmaceuticals/guidelines/production, accessed 13 December 2024).
- Member State Mechanism [internet]. Geneva: World Health Organization; 2024 (https://www.who.int/teams/regulation-prequalification/incidents-and-SF/mechanism, accessed 26 November 2024).
- Norms and standards of pharmaceuticals [internet]. Geneva: World Health Organization; 2024 (https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/norms-and-standards-for-pharmaceuticals, accessed 26 November 2024).
- Substandard and falsified medical products: advice to patients and consumers [internet]. Geneva: World Health Organization; 2019 (https://www.who.int/news-room/questions-and-answers/item/substandard-and-falsified-medical-products-advice-to-patients-and-consumers, accessed 26 November 2024).
- Tenth meeting of the Members State Mechanism on SFMP. Develop guidance on strategies to enable national/regional regulatory authorities to address the distribution or supply of substandard and falsified medical products via the internet. Report on activity. Geneva: World Health Organization; 2021 (https://apps.who.int/gb/sf/pdf_files/MSM10/A_MSM10_10-en.pdf, accessed 26 November 2024).
- The WHO Member State mechanism on substandard and falsified medical products: how WHO Member States work together to increase access to safe, effective and quality medicines, vaccines and other medical products, update 2022. Geneva: World Health Organization; 2022 (https://iris.who.int/handle/10665/365562, accessed 26 November 2024).

Peer-reviewed scientific literature

- Ndomondo-Sigonda M, Azatyan S, Doerr P, Agaba C, Harper KN. Best practices in the African Medicines Regulatory Harmonization initiative: Perspectives of regulators and medicines manufacturers. PLOS Glob Public Health. 2023;26;3(4):e0001651. https://doi.org/10.1371/journal.pgph.0001651
- Newton PN, Amin AA, Bird C, Passmore P, Dukes G, Tomson G, et al. The primacy of public health: considerations in defining poor quality medicines. PLoS Med. 2011; 8(12): e1001139. https://doi.org/10.1371/journal.pmed.1001139
- Newton PN, Bond KC; Oxford Statement signatories. Global access to quality-assured medical products: the Oxford Statement and call to action. Lancet Glob Health. 2019;7(12):e1609–11. https://doi.org/10.1016/S2214-109X(19)30426-7
- Orubu ESF, Ching C, Zaman MH, Wirtz VJ. Tackling the blind spot of poor-quality medicines in universal health coverage. Review J Pharm Policy Pract. 2020:13:40. https://doi.org/10.1186/s40545-020-00208-4
- Ozawa S, Evans DR, Bessias S, Haynie DG, Yemeke TT, Laing SK, et al. Prevalence and estimated economic burden of substandard and falsified medicines in low- and middle-income countries: a systematic review and meta-analysis. *JAMA Netw Open.* 2018;1(4):e181662. https://doi.org/10.1001/jamanetworkopen.2018.1662

- Ozawa S, Higgins CR, Yemeke TT, Nwokike JI, Evans L, Hajjou M, et al. Importance of medicine quality in achieving universal health coverage. PLoS One. 2020;15(7):e0232966. https://doi.org/10.1371/journal.pone.0232966
- Rojas-Cortés R. Substandard, falsified and unregistered medicines in Latin America, 2017–2018. Rev Panam Salud Publica. 2020;44:e125. https://doi.org/10.26633/RPSP.2020.125

Online tools

- Antimalarial quality literature surveyor. Worldwide Antimalarial Resistance Network; 2024 (http://www.wwarn.org/aqsurveyor/#0, accessed 26 November 2024).
- Medicines quality scientific literature surveyor. Infectious Disease Data Observatory (IDDO); 2024 (https://www.iddo.org/mq-scientific-literature-surveyor, accessed 26 November 2024).

5.3.3 Module B. Prevent

WHO documents

- Annex 2. Good manufacturing practices for pharmaceutical products: main principles. In: Forty-eighth report of the WHO Expert Committee on specifications for pharmaceutical preparations. Geneva: World Health Organization; 2014 (https://iris.who.int/handle/10665/112733, accessed 26 November 2024).
- Annex 7. Good storage and distribution practices for medical products. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations: fifty-fourth report. Geneva: World Health Organization; 2020 (https://iris.who.int/handle/10665/331814, accessed 26 November 2024).
- Annex 8. Good pharmacy practice: standards for quality of pharmacy services (joint FIP/WHO). In: Forty-fifth report of the WHO Expert Committee on specifications for pharmaceutical preparations. Geneva: World Health Organization; 2011 (https://iris.who.int/handle/10665/44079, accessed 26 November 2024).
- "IDEAS": a global communications framework to help combat the threat from substandard and falsified medical products. Geneva: World Health Organization; 2018 (https://apps.who.int/gb/sf/pdf_files/msm7/a_msm7_4-en.pdf, accessed 26 November 2024).
- Policy paper on traceability of medical products. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/340237, accessed 26 November 2024).
- WHO Strategic Communication Framework for effective communications. Geneva: World Health organization; 2017 (https://www.who.int/docs/default-source/documents/communicating-for-health/communication-framework.pdf, accessed 26 November 2024).

Peer-reviewed scientific literature

- Gray NJ, Barr RD, Karekezi C, Chanoine JP. Substandard and falsified medicines for children: UHC has a preventive role. Lancet Child Adolesc Health. 2023;7(12):821–3. https://doi.org/10.1016/S2352-4642(23)00227-4
- Nebot Giralt A, Bourasseau A, White G, Pouget C, Tabernero P, Van Assche K, et al. Quality assurance systems of pharmaceutical distributors in low-income and middle-income countries: weaknesses and ways forward. BMJ Glob Health. 2020;5(10):e003147. https://doi.org/10.1136/bmjgh-2020-003147
- Schier J, Chang A, Kapil V. Medication-associated diethylene glycol mass poisoning – a preventable cause of illness and death. N Engl J Med. 2023;388(13):1156–7. https://doi.org/10.1056/NEJMp2215840
- Tabernero P, Newton PN. Estimating the prevalence of poor-quality anti-TB medicines: a neglected risk for global TB control and resistance. BMJ Glob Health. 2023;8(7):e012039. https://doi.org/10.1136/bmjgh-2023-012039

- 't Hoen EFM, Hogerzeil HV, Quick JD, Sillo H. A quiet revolution in global public health: the World Health Organization's prequalification of medicines programme. J Public Health Policy. 2014;35(2):137–61. https://doi.org/10.1057/jphp.2013.53
- Walker EJ, Peterson GM, Grech J, Paragalli E, Thomas J. Are we doing enough to prevent poor-quality antimalarial medicines in the developing world? BMC Public Health. 2018;18(1):630. https://doi.org/10.1186/s12889-018-5521-7

Non-WHO guidelines

- Medisafe national pharmaceutical supply chain security guide. Paris: Expertise France; 2023 (https://cbrn-risk-mitigation.network.europa.eu/document/download/4306abda-7800-48ec-a913-124150226c7c_en?filename=SUPPLY%20CHAIN%20SECURITY%20GUIDE%20BD.PDF, accessed 26 Nov 2024).
- Pharmacists in the supply chain: the role of the medicines expert in ensuring quality and availability. The Hague: International Pharmaceutical Federation; 2017 (https://www.fip.org/file/1344, accessed 26 November 2024).
- Tool for visual inspection of medicines. Geneva: World Health Professions Alliance; 2018 (https://whpa.org/sites/default/files/2018-12/Toolkit_BeAware_Inspection.pdf, accessed 26 November 2024).

5.3.4 Module C. Detect

WHO surveys

- Annex 5. WHO guidance on testing of "suspect" falsified medicines. In: Fifty-second report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations. Geneva: World Health Organization; 2018 (https://iris.who.int/handle/10665/272452, accessed 27 November 2024).
- Guidance for post-market surveillance and market surveillance of medical devices, including in vitro diagnostics. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/337551, accessed 26 November 2024).
- Survey of the quality of selected antimalarial medicines circulating in six countries of sub-Saharan Africa. Copenhagen: World Health Organization Regional Office for Europe; 2011 (https://www.afro.who.int/publications/survey-quality-selected-antimalarial-medicines-circulating-six-countries-sub-saharan, accessed 26 November 2024).
- Survey of the quality of anti-tuberculosis medicines circulating in selected newly independent states of the former Soviet Union. Copenhagen: World Health Organization Regional Office for Europe; 2011 (https://www.who.int/news/item/04-02-2012-survey-of-the-quality-of-anti-tuberculosis-medicines-circulating-in-selected-newly-independent-states-of-the-former-soviet-union, accessed 26 November 2024).
- Survey of the quality of medicines identified by the United Nations commission on life-saving commodities for women and children. Geneva: World Health Organization; 2016 (https://iris.who.int/handle/10665/255550, accessed 27 November 2024).
- Survey of the quality of selected antiretroviral medicines circulating in five African countries. Geneva: World Health Organization; 2019 (https://iris.who.int/handle/10665/332296, accessed 27 November 2024).

Online tools

- Fake medicines. Lyon: INTERPOL; 2024 (https://www.interpol.int/fr/Infractions/Marchandises-illicites/Achetez-en-toute-securite/Faux-medicaments#Comment%20rep%C3%A9rer%20Les%20Faux%20Produits%20M%C3%A9dicaux%20, accessed 26 November 2024).
- Fake medicines are a dangerous threat in Africa: 3 ways to spot them. Arcadia: South African Health Products Regulatory Authority (SAHPRA); 2023 (https://www.sahpra.org.za/news-and-updates/fake-medicines-are-a-dangerous-threat-in-africa-3-ways-to-spot-them/, accessed 26 November 2024).
- Nkansah P, Smine K, Pribluda V, Phanouvong S, Dunn C, Walfish S, et al. Guidance for implementing risk-based postmarketing quality surveillance in low- and middle-income countries. Rockville, MD: United States Pharmacopeia; 2017 (https://www.usp-pqm.org/sites/default/files/pqms/article/risk-based-post-marketing-surveillance-feb-2018.pdf, accessed 26 November 2024).
- Supply chain security toolkit for medical products. Singapore: Asia-Pacific Economic Cooperation (APEC); 2024 (https://www.usp.org/apec-supply-chain-security-toolkit, accessed 26 November 2024).

Peer-reviewed scientific literature

- Dhakal N, Gyanwali P, Humagain B, Bc R, Jha N, Sah P, et al. Assessment of quality of essential medicines in public health care facilities of Nepal: findings of nationwide study. PLOS Glob Public Health. 2023;3(5):e0001841. https://doi.org/10.1371/journal.pgph.0001841
- Gnegel G, Häfele-Abah C, Neci R; Difäm-EPN Minilab Network, Heide L. Surveillance for substandard and falsified medicines by local faith-based organizations in 13 low- and middle-income countries using the GPHF Minilab. Sci Rep. 2022;12(1):13095. https://doi.org/10.1038/s41598-022-17123-0
- Newton PN, Lee SJ, Goodman C, Fernández FM, Yeung S, Phanouvong S, et al. Guidelines for field surveys of the quality of medicines: a proposal. PLoS Med. 2009;6(3):e52. https://doi.org/10.1371/journal.pmed.1000052
- Roth L, Biggs KB, Bempong DK. Substandard and falsified medicine screening technologies. AAPS Open. 2019;5:2. https://doi.org/10.1186/s41120-019-0031-y
- Schiavetti B, Wynendaele E, Melotte V, Van der Elst J, De Spiegeleer B, Ravinetto R, et al. A simplified checklist for the visual inspection of finished pharmaceutical products: a way to empower frontline health workers in the fight against poor-quality medicines. J Pharm Policy Practice. 2020; 13:9. https://doi.org/10.1186/s40545-020-00211-9
- Tabernero P, Parker M, Ravinetto R, Phanouvong S, Yeung S, Kitutu FE, et al. Ethical challenges in designing and conducting medicine quality surveys. Trop Med Int Health. 2016;21(6):799–806. https://doi.org/10.1111/tmi.12707
- Umar TP, Jain N, Azis H. Endemic rise in cases of acute kidney injury in children in Indonesia and Gambia: what is the likely culprit and why? Kidney Int. 2023;103(3):444–7. https://doi.org/10.1016/j.kint.2022.12.004
- Vickers S, Bernier M, Zambrzycki S, Fernandez FM, Newton PN, Caillet C. Field detection devices for screening the quality of medicines: a systematic review. BMJ Global Health. 2018;3(4):e000725. https://doi.org/10.1136/bmjgh-2018-00072
- Waffo Tchounga CA, Sacré PY, Ravinetto R, Lieberman M, Hamuli Ciza P, Ngono Mballa R, et al. Usefulness of medicine screening tools in the frame of pharmaceutical post-marketing surveillance. PLoS One. 2023;18(8):e0289865. https://doi.org/10.1371/journal.pone.0289865

5.3.5 Module D. Response

WHO surveys

- Rapid risk assessment of acute public health events. Geneva: World Health Organization; 2012 (https://iris.who.int/handle/10665/70810, accessed 26 November 2024).

Peer-reviewed scientific literature

- Ali GKM, Alfadl AA, Fathelrahman AI. Newspapers' coverage of contaminated intravenous fluids from an Indian manufacturer distributed by Public Central Medical Supplies in Sudan: lessons to be learned. Health Policy. 2011;101(2):172–7. https://doi.org/10.1016/j.healthpol.2010.12.004
- Barbe B, Verdonck K, El-Safi S, Khanal B, Teav S, Lilo Kalo JR, et al. Rapid diagnostic tests for neglected infectious diseases: case study highlights need for customer awareness and postmarket surveillance. PLoS Negl Trop Dis. 2016;10(11): e0004655. https://doi.org/10.1371/journal.pntd.0004655
- Macé C, Nikiema JB, Sarr OS, Hamuli PC, Djang'eing'a Marini R, Neci RC, et al. The response to substandard and falsified medical products in francophone sub-Saharan African countries: weaknesses and opportunities. J Pharm Policy Pract. 2023;16(1):117. https://doi.org/10.1186/s40545-023-00628-y
- Nwokike J, Clark A, Nguyen PP. Medicines quality assurance to fight antimicrobial resistance. Bull World Health Organ. 2018;96(2):135–7. https://doi.org/10.2471/BLT.17.199562
- Olliaro E, Olliaro P, Ho CWL, Ravinetto R. Perspective piece legal uncertainty—the gray area around substandard medicines: where public health meets law. Am J Trop Med Hyg. 2020;102(2):262–7. https://doi.org/10.4269/ajtmh.19-0645
- Qaiser M, Hilton T, Saeed Bukhari SK, Zloh M, Phanouvong S. How a tragedy became a catalyst for sustainable improvement in medicine safety. Lancet Glob Health. 2024;12(3):e376–7. https://doi.org/10.1016/S2214-109X(24)00026-3
- Thiagarajan K. Indian government cracks down on 18 drug companies for poor quality manufacturing. BMJ. 2023;381:785. https://doi.org/10.1136/bmj.p785